JP2025516186A5 - - Google Patents
Info
- Publication number
- JP2025516186A5 JP2025516186A5 JP2024563225A JP2024563225A JP2025516186A5 JP 2025516186 A5 JP2025516186 A5 JP 2025516186A5 JP 2024563225 A JP2024563225 A JP 2024563225A JP 2024563225 A JP2024563225 A JP 2024563225A JP 2025516186 A5 JP2025516186 A5 JP 2025516186A5
- Authority
- JP
- Japan
- Prior art keywords
- aav
- polynucleotide
- disease
- use according
- expression vector
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263363529P | 2022-04-25 | 2022-04-25 | |
| US63/363,529 | 2022-04-25 | ||
| PCT/US2023/066117 WO2023212521A2 (en) | 2022-04-25 | 2023-04-24 | Treatments of disorders of myelin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516186A JP2025516186A (ja) | 2025-05-27 |
| JP2025516186A5 true JP2025516186A5 (https=) | 2026-05-01 |
Family
ID=88519762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563225A Pending JP2025516186A (ja) | 2022-04-25 | 2023-04-24 | ミエリンの障害の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250171778A1 (https=) |
| EP (1) | EP4514402A2 (https=) |
| JP (1) | JP2025516186A (https=) |
| CN (1) | CN119451703A (https=) |
| WO (1) | WO2023212521A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025160429A1 (en) * | 2024-01-26 | 2025-07-31 | Genzyme Corporation | Artificial micrornas targeting snca |
| WO2025228394A1 (zh) * | 2024-04-30 | 2025-11-06 | 艾码生物科技(南京)有限公司 | 递送初级微小rna的方法及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL248102B (en) * | 2014-05-02 | 2022-07-01 | Genzyme Corp | aav vectors for gene therapy of the central nervous system and retina |
| CA3193406A1 (en) * | 2020-09-21 | 2022-03-24 | Asklepios Biopharmaceutical, Inc. | Methods for treating neurological disease |
-
2023
- 2023-04-24 CN CN202380049027.7A patent/CN119451703A/zh active Pending
- 2023-04-24 US US18/859,602 patent/US20250171778A1/en active Pending
- 2023-04-24 JP JP2024563225A patent/JP2025516186A/ja active Pending
- 2023-04-24 EP EP23797461.3A patent/EP4514402A2/en active Pending
- 2023-04-24 WO PCT/US2023/066117 patent/WO2023212521A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250011783A1 (en) | Gene therapy for neurodegenerative disorders | |
| JP2025516186A5 (https=) | ||
| US20250161485A1 (en) | Aav capsid variants and uses thereof | |
| BR112020008033A2 (pt) | terapias gênicas para doença neurodegenerativa | |
| JP2006515864A5 (https=) | ||
| WO2024006741A1 (en) | Aav capsid variants and uses thereof | |
| WO2024011112A1 (en) | Aav capsid variants and uses thereof | |
| WO2025038430A1 (en) | Aav capsid variants and uses thereof | |
| CN121152795A (zh) | 工程化aav衣壳stac-102的适合度成熟 | |
| JP2024539170A (ja) | 条件付きで活性化可能な核酸構築物及び神経学的疾患の治療におけるその使用 | |
| US20250171778A1 (en) | Treatments of Disorders of Myelin | |
| JPWO2023154693A5 (https=) | ||
| US20200283800A1 (en) | Gene therapies for neurodegenerative diseases | |
| WO2025147436A1 (en) | Aav capsid variants and uses thereof | |
| AU2024253981A1 (en) | Compositions and methods for treating cag repeat diseases | |
| US20250025575A1 (en) | Compositions and Methods for Cell-Specific Expression of Target Genes | |
| US20220081690A1 (en) | Use of mir-204 inhibitor to increase nurr1 protein expression | |
| US10426846B2 (en) | OLIG1 mini-promoters: PIe305 |